VCd

Daratumumab-VCd Combination Significantly Improves Survival in Newly Diagnosed AL Amyloidosis: Insights from the ANDROMEDA Trial

The ANDROMEDA phase 3 trial demonstrates that adding subcutaneous daratumumab to VCd therapy markedly improves hematologic and organ responses, leading to better progression-free and overall survival in newly diagnosed AL amyloidosis patien